Brief: Selecta Biosciences Says Phase 3 Dissolve Program Of SEL-212 In Chronic Refractory Gout Meets Primary Endpoint

Cartesian Therapeutics

21/03/2023 07:35

March 21 (Reuters) - Selecta Biosciences Inc  SELB.O :
    * PHASE 3 DISSOLVE PROGRAM OF SEL-212 IN CHRONIC REFRACTORY
GOUT
MEETS PRIMARY ENDPOINT
    * FAVORABLE SAFETY PROFILE WITH 3.4% OF PATIENTS WITH
INFUSION
REACTIONS AT HIGH DOSE
    * SELECTA-POISED TO MOVE SEL-212 FORWARD TOWARDS
COMMERCIALIZATION,  INTEND TO FILE MARKETING AUTHORIZATION
APPLICATIONS IN US IN FIRST HALF 2024
    * SELECTA BIOSCIENCES - THERE WAS ONE DEATH IN SIX-MONTH
EXTENSION
PHASE OF TRIAL, WHICH WAS CAUSED BY MOTOR VEHICLE ACCIDENT
UNRELATED TO STUDY DRUG
    * RESPONSE RATE OF 56% IN PATIENTS TREATED MONTHLY WITH HIGH
DOSE
SEL-212 IN DISSOLVE I AND 47% IN DISSOLVE II

Source text for Eikon:  ID:nGNX21KgRF 
Further company coverage:  SELB.O 

 ((Reuters.Briefs@thomsonreuters.com;))